No association was found between variants of these genes and disease recurrence in tamoxifen-treated patients.
Previous studies have provided conflicting data on whether the presence of certain polymorphisms of cytochrome P450 2D6 (CYP2D6) or UDP-glucuronosyltransferase-2B7 (UGT2B7) can predict the efficacy of treatment with tamoxifen in patients with breast cancer. Now, two studies have addressed this issue further.
Regan and colleagues studied 4861 postmenopausal patients with hormone receptor–positive breast cancer who were randomized to receive tamoxifen, letrozole, or both. Extracted DNA was used to genotype CYP2D6 and classify each patient as a poor metabolizer (PM), intermediate metabolizer (IM), or extensive metabolizer (EM). No significant association was observed between CYP2D6 phenotype and disease recurrence in tamoxifen-treated patients.…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)